Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01670994 · OUTCOME

Number of Participants With Treatment-Related Adverse Events

QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2024-06-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
7 weeks

What was measured

Number of treatment related AEs that occur or worsen after the first dose of study treatment

Groups in this outcome

ALT-801 0.04mg/kg

ALT-801: Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle

ALT-801 0.06mg/kg

ALT-801: Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
ALT-801 0.04mg/kg3
ALT-801 0.06mg/kg3

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
ALT-801 0.04mg/kg3Not reportedNot reportedNot reportedNot reported
ALT-801 0.06mg/kg3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        3
      2. group Id
        OG001
        value
        3
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      3
    units
    Participants
description
Number of treatment related AEs that occur or worsen after the first dose of study treatment
groups
  1. description
    ALT-801: Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle
    id
    OG000
    title
    ALT-801 0.04mg/kg
  2. description
    ALT-801: Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle
    id
    OG001
    title
    ALT-801 0.06mg/kg
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
7 weeks
title
Number of Participants With Treatment-Related Adverse Events
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice